- Home
- TNGX vs GEVO Comparison
TNGX vs GEVO Comparison
Compare TNGX & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- GEVO
- Stock Information
- Founded
- TNGX 2014
- GEVO 2005
- Country
- TNGX United States
- GEVO United States
- Employees
- TNGX N/A
- GEVO N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- GEVO Major Chemicals
- Sector
- TNGX Health Care
- GEVO Industrials
- Exchange
- TNGX Nasdaq
- GEVO Nasdaq
- Market Cap
- TNGX 317.4M
- GEVO 330.4M
- IPO Year
- TNGX N/A
- GEVO 2011
- Fundamental
- Price
- TNGX $1.76
- GEVO $1.31
- Analyst Decision
- TNGX Strong Buy
- GEVO Buy
- Analyst Count
- TNGX 7
- GEVO 2
- Target Price
- TNGX $12.33
- GEVO $8.63
- AVG Volume (30 Days)
- TNGX 801.9K
- GEVO 3.8M
- Earning Date
- TNGX 05-07-2025
- GEVO 05-01-2025
- Dividend Yield
- TNGX N/A
- GEVO N/A
- EPS Growth
- TNGX N/A
- GEVO N/A
- EPS
- TNGX N/A
- GEVO N/A
- Revenue
- TNGX $42,069,000.00
- GEVO $15,589,000.00
- Revenue This Year
- TNGX N/A
- GEVO N/A
- Revenue Next Year
- TNGX N/A
- GEVO $917.63
- P/E Ratio
- TNGX N/A
- GEVO N/A
- Revenue Growth
- TNGX 15.17
- GEVO 16.59
- 52 Week Low
- TNGX $1.71
- GEVO $0.48
- 52 Week High
- TNGX $12.02
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- TNGX 33.97
- GEVO 41.82
- Support Level
- TNGX $1.80
- GEVO $1.19
- Resistance Level
- TNGX $2.04
- GEVO $1.49
- Average True Range (ATR)
- TNGX 0.18
- GEVO 0.11
- MACD
- TNGX 0.01
- GEVO 0.03
- Stochastic Oscillator
- TNGX 20.19
- GEVO 47.06
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment, Renewable Natural Gas Segment, and the Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure.